Literature DB >> 24353120

Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study).

Hendrik Manner1, Thomas Rabenstein2, Oliver Pech3, Kirsten Braun1, Andrea May1, Juergen Pohl1, Angelika Behrens1, Michael Vieth4, Christian Ell1.   

Abstract

BACKGROUND AND STUDY AIM: It is commonly assumed that ablation of any remaining Barrett's epithelium after endoscopic resection of early Barrett's neoplasia improves outcome by reducing the rate of metachronous lesions, but this has not yet been evaluated in a randomized trial. The aim of this study was to compare argon plasma coagulation (APC) with surveillance only for the management of residual Barrett's epithelium following endoscopic resection. PATIENTS AND METHODS: Patients in whom focal early Barrett's neoplasia (high grade intraepithelial neoplasia [HGIN] or mucosal cancer) had been curatively resected by endoscopy were randomly assigned to undergo ablation of the residual Barrett's segment by APC or surveillance only; pH-metry-adjusted proton pump inhibitor therapy was administered in both groups. The main outcome parameter was recurrence-free survival. Follow-up endoscopies with biopsies in cases of further residual Barrett's epithelium were carried out at 6-monthly intervals in both groups.
RESULTS: A total of 63 patients (57 male [90.5%]) were included in the study (ablation group n=33; surveillance group n=30). For complete Barrett's ablation, a mean number of 4±1.6 APC sessions were required (range 2-7). The mean follow-up duration did not differ significantly between ablation (28.2±13.7 months, range 0-44) and surveillance patients (24.7±14.8 months, range 0-45; P=0.159). The number of secondary lesions was 1 in the ablation group (3%), and 11 in the surveillance group (36.7%), leading to significantly higher recurrence-free survival for the patients undergoing ablation (P=0.005).
CONCLUSIONS: Thermal ablation of residual Barrett's epithelium leads to a significant reduction in neoplasia recurrence rate compared with a surveillance strategy during a limited follow-up of 2 years. A longer follow-up duration may have led to a relatively higher rate of secondary neoplasia in both groups of patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24353120     DOI: 10.1055/s-0033-1358813

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  30 in total

1.  Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.

Authors:  Mariana Milashka; Annabelle Calomme; Jean Luc Van Laethem; Daniel Blero; Pierre Eisendrath; Olivier Le Moine; Jacques Devière
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

2.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

Review 3.  Endoscopic options for treatment of dysplasia in Barrett's esophagus.

Authors:  R Brooks Vance; Kerry B Dunbar
Journal:  World J Gastrointest Endosc       Date:  2015-12-25

Review 4.  Endoscopic options for early stage esophageal cancer.

Authors:  Pari M Shah; Hans Gerdes
Journal:  J Gastrointest Oncol       Date:  2015-02

Review 5.  Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.

Authors:  Magnus Halland; David Katzka; Prasad G Iyer
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

6.  The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study.

Authors:  Hendrik Manner; Alexander Neugebauer; Marcus Scharpf; Kirsten Braun; Andrea May; Christian Ell; Falko Fend; Markus D Enderle
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

7.  Current status of management of malignant disease: what are the options for premalignant lesions of the esophagus and stomach?

Authors:  Jeffrey Michael Marks; Andrea Jo King
Journal:  J Gastrointest Surg       Date:  2014-11-14       Impact factor: 3.452

Review 8.  Barrett's esophagus: diagnosis and management.

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2017-01-18       Impact factor: 9.427

9.  Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.

Authors:  Srinadh Komanduri; Peter J Kahrilas; Kumar Krishnan; Tim McGorisk; Kiran Bidari; David Grande; Laurie Keefer; John Pandolfino
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

Review 10.  [Barrett's esophagus].

Authors:  J Labenz
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.